Changeflow GovPing Healthcare & Life Sciences Nucleic Acid siRNA Anti-Hair Loss Patent Applic...
Routine Notice Added Final

Nucleic Acid siRNA Anti-Hair Loss Patent Application

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published patent application US20260109987A1, filed October 21, 2025, by CANAAN PARTNERS INC. and ten named inventors, covering a siRNA composition that silences the androgen receptor (AR) gene for anti-hair loss and oil control effects, combined with an ionic liquid delivery system enabling transdermal penetration to the dermis layer. The application also claims antibacterial activity against Propionibacterium acnes. CPC classifications include C12N 15/1138, A61K 47/186, and A61P 17/14.

“The small interfering RNA (siRNA) sequence has a significant silencing effect for the androgen receptor (AR) target gene.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 258 changes logged to date.

What changed

The USPTO published patent application US20260109987A1 covering a novel siRNA sequence that silences the androgen receptor (AR) target gene, formulated with an ionic liquid or ionic liquid-lipid combination for transdermal delivery. The composition is designed to penetrate the epidermis, reach the dermis, and exert AR-silencing effects with downstream regulatory impact on genes and proteins controlled by AR. The application also claims antibacterial activity against Propionibacterium acnes.

R&D-intensive companies developing siRNA-based dermatological or hair-loss treatments should monitor this application's claims, particularly the specific AR-targeting sequence and the ionic liquid delivery mechanism, as the granted patent could create freedom-to-operate considerations for competing transdermal RNA delivery products.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PREPARATION AND USE OF NUCLEIC ACID WITH ANTI-HAIR LOSS AND OIL CONTROL EFFECTS AND COMPOSITION INCLUDING NUCLEIC ACID

Application US20260109987A1 Kind: A1 Apr 23, 2026

Assignee

CANAAN PARTNERS INC.

Inventors

Fang WANG, Haowei CHEN, Jie TAN, Jiaheng ZHANG, Nanxi XIANG, Lijuan LIU, Chunqiao ZHANG, Chengyu WU, Mingqing ZHOU, Jichuan ZHANG

Abstract

A preparation and a use of a nucleic acid with anti-hair loss and oil control effects and a composition including the nucleic acid are provided. The small interfering RNA (siRNA) sequence has a significant silencing effect for the androgen receptor (AR) target gene. The composition prepared from an ionic liquid or a combination of an ionic liquid and a lipid exhibits a prominent delivery effect for water-soluble nucleic acid molecules. The composition can penetrate cells and enter cell nuclei to achieve an AR-silencing effect, and can provide significant regulatory effects for downstream target genes or proteins regulated by AR and comprehensive anti-hair loss and oil control effects. The composition exhibits a prominent transdermal permeation-promoting effect, and can permeate the epidermis layer and reach the dermis layer to exert remarkable anti-hair loss and oil control effects. In addition, the composition has a high antibacterial activity against Propionibacterium acnes.

CPC Classifications

C12N 15/1138 A61K 47/186 A61K 47/24 A61K 47/28 A61K 47/32 A61K 47/42 A61P 17/14 C12N 2310/14

Filing Date

2025-10-21

Application No.

19363685

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent examination IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!